Marilyn’s Message January 2018
“Fail faster” is a saying in drug research. In 2014, the Tufts Center for the Study of Drug Development estimated that the average cost of bringing a new drug through…
Continue Reading“Fail faster” is a saying in drug research. In 2014, the Tufts Center for the Study of Drug Development estimated that the average cost of bringing a new drug through…
Continue ReadingImmusanT, a biotechnology company focusing on protecting patients with celiac disease against the effects of gluten, has announced that it has secured $40 million in funding to advance its drug,…
Continue ReadingCeliac Disease Foundation is proud to have been a funder and to participate on the Steering Committee for the FDA Gastroenterology Regulatory Endpoints and Advancement of Therapeutics (GREAT3) workshop. Conceived…
Continue ReadingCeliac Disease Foundation is pleased to announce the March 30-31, 2015, U.S. Food and Drug Administration (FDA) public workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3). This scientific meeting will address endpoints and outcome measures for clinical trials for products intended to treat adult and/or pediatric celiac disease and inflammatory bowel disease.
Continue Reading